Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Influenza Vaccine Influvac Available in Germany with Italian Label

Influvac is an active immunisation vaccine used to prevent influenza in adults, including pregnant women, and in children aged six months and up. The vaccine's active substances are surface antigens (haemagglutinin and neuraminidase) of the influenza virus strains recommended by the World Health Organization (WHO) for the 2025/26 season.  

Many of the trivalent influenza vaccines planned for the current season have already been reported as sold out. In order to meet the additional demand for the 2025/26 season, the Paul-Ehrlich-Institut has permitted the marketing authorisation holder Viatris Healthcare GmbH, as an exception pursuant to section 10 (1a) and section 11 (1c) of the Medicinal Products Act (Arzneimittelgesetz, AMG), to place Influvac on the market in Germany with Italian labelling from 15 February to 30 April 2026. This product is pharmaceutically identical to the product with German labelling, differing only in the packaging and in the commercial name ("Influvac S" instead of "Influvac"). 

Details

  • The commercial name of this Italian-labelled product is "Influvac S" (see photos below).
  • The text on the syringe label, in the package leaflet, and on the folding box is in Italian.
  • The German package leaflet and the summary of product characteristics are available for download on this page.
  • Pharmaceutical form: suspension for injection in a pre-filled syringe
  • PZN: 20373275
  • Batch number: L11
  • Expiration date: 30 April 2026

Image / Video 1 / 4

Vaccine Influvac Front  of packaging with Italian labelling Vaccine Influvac Front of packaging with Italian labelling. Source: Viatris Healthcare GmbH

Pagination

How Should the Vaccine Be Used?

The instructions listed in the package leaflet must be followed.

Background

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, is the higher federal authority responsible for the quality, safety and efficacy of vaccines in Germany and for the official batch release of vaccines and biomedicines. It also advocates for the availability of these medicines.

An up-to-date overview of current supply shortages of human vaccines in Germany can be found on the website of the Paul-Ehrlich-Institut.

Our email newsletter "Safety and Availability – Information on medicines safety, instruction notes on human vaccine supply shortages" provides regular information about current availability and supply shortages.

Updated: 13.02.2026